Literature DB >> 25641990

Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to HIV vaccine efficacy trials.

Peter B Gilbert1, Yanqing Sun2.   

Abstract

This article develops hypothesis testing procedures for the stratified mark-specific proportional hazards model in the presence of missing marks. The motivating application is preventive HIV vaccine efficacy trials, where the mark is the genetic distance of an infecting HIV sequence to an HIV sequence represented inside the vaccine. The test statistics are constructed based on two-stage efficient estimators, which utilize auxiliary predictors of the missing marks. The asymptotic properties and finite-sample performances of the testing procedures are investigated, demonstrating double-robustness and effectiveness of the predictive auxiliaries to recover efficiency. The methods are applied to the RV144 vaccine trial.

Entities:  

Keywords:  Auxiliary marks; augmented inverse probability weighting; competing risks failure time data; genetic data; proportional hazards model; semiparametric model

Year:  2015        PMID: 25641990      PMCID: PMC4310507          DOI: 10.1111/rssc.12067

Source DB:  PubMed          Journal:  J R Stat Soc Ser C Appl Stat        ISSN: 0035-9254            Impact factor:   1.864


  13 in total

1.  The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.

Authors:  Peter B Gilbert; Ian W McKeague; Yanqing Sun
Journal:  Biostatistics       Date:  2007-08-17       Impact factor: 5.899

2.  HIV vaccine research: the way forward.

Authors:  Anthony S Fauci; Margaret I Johnston; Carl W Dieffenbach; Dennis R Burton; Scott M Hammer; James A Hoxie; Malcolm Martin; Julie Overbaugh; David I Watkins; Adel Mahmoud; Warner C Greene
Journal:  Science       Date:  2008-07-25       Impact factor: 47.728

3.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS.

Authors:  Yanqing Sun; Peter B Gilbert; Ian W McKeague
Journal:  Ann Stat       Date:  2009-02-01       Impact factor: 4.028

6.  Estimation of Stratified Mark-Specific Proportional Hazards Models with Missing Marks.

Authors:  Yanqing Sun; Peter B Gilbert
Journal:  Scand Stat Theory Appl       Date:  2012-03       Impact factor: 1.396

7.  Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.

Authors:  Morgane Rolland; Sodsai Tovanabutra; Allan C deCamp; Nicole Frahm; Peter B Gilbert; Eric Sanders-Buell; Laura Heath; Craig A Magaret; Meera Bose; Andrea Bradfield; Annemarie O'Sullivan; Jacqueline Crossler; Teresa Jones; Marty Nau; Kim Wong; Hong Zhao; Dana N Raugi; Stephanie Sorensen; Julia N Stoddard; Brandon S Maust; Wenjie Deng; John Hural; Sheri Dubey; Nelson L Michael; John Shiver; Lawrence Corey; Fusheng Li; Steve G Self; Jerome Kim; Susan Buchbinder; Danilo R Casimiro; Michael N Robertson; Ann Duerr; M Juliana McElrath; Francine E McCutchan; James I Mullins
Journal:  Nat Med       Date:  2011-02-27       Impact factor: 53.440

8.  Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Authors:  Penny L Moore; Nthabeleng Ranchobe; Bronwen E Lambson; Elin S Gray; Eleanor Cave; Melissa-Rose Abrahams; Gama Bandawe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

9.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Authors:  Morgane Rolland; Paul T Edlefsen; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Tomer Hertz; Allan C deCamp; Chris Carrico; Sergey Menis; Craig A Magaret; Hasan Ahmed; Michal Juraska; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; Jason S McLellan; Ivelin Georgiev; Peter D Kwong; Jonathan M Carlson; Nelson L Michael; William R Schief; Peter B Gilbert; James I Mullins; Jerome H Kim
Journal:  Nature       Date:  2012-09-10       Impact factor: 49.962

10.  HIV-specific probabilistic models of protein evolution.

Authors:  David C Nickle; Laura Heath; Mark A Jensen; Peter B Gilbert; James I Mullins; Sergei L Kosakovsky Pond
Journal:  PLoS One       Date:  2007-06-06       Impact factor: 3.240

View more
  12 in total

1.  Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy.

Authors:  Peter B Gilbert; Ying Huang
Journal:  Epidemiol Methods       Date:  2016-01-23

2.  Estimation of a Semiparametric Varying-Coefficient Mixed Regressive Spatial Autoregressive Model.

Authors:  Yanqing Sun; Yuanqing Zhang; Jianhua Z Huang
Journal:  Econom Stat       Date:  2017-06-09

3.  Analysis of the time-varying Cox model for the cause-specific hazard functions with missing causes.

Authors:  Fei Heng; Yanqing Sun; Seunggeun Hyun; Peter B Gilbert
Journal:  Lifetime Data Anal       Date:  2020-04-09       Impact factor: 1.588

4.  Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark.

Authors:  Yanqing Sun; Mei Li; Peter B Gilbert
Journal:  Comput Stat Data Anal       Date:  2014-12-03       Impact factor: 1.681

5.  Estimation of Stratified Mark-Specific Proportional Hazards Models under Two-Phase Sampling with Application to HIV Vaccine Efficacy Trials.

Authors:  Guangren Yang; Yanqing Sun; Li Qi; Peter B Gilbert
Journal:  Stat Biosci       Date:  2016-10-27

6.  Mark-specific additive hazards regression with continuous marks.

Authors:  Dongxiao Han; Liuquan Sun; Yanqing Sun; Li Qi
Journal:  Lifetime Data Anal       Date:  2016-05-11       Impact factor: 1.588

7.  Fitting Multilevel Vector Autoregressive Models in Stan, JAGS, and Mplus.

Authors:  Yanling Li; Julie Wood; Linying Ji; Sy-Miin Chow; Zita Oravecz
Journal:  Struct Equ Modeling       Date:  2021-09-14       Impact factor: 6.181

8.  A Hybrid Approach for the Stratified Mark-Specific Proportional Hazards Model with Missing Covariates and Missing Marks, with Application to Vaccine Efficacy Trials.

Authors:  Yanqing Sun; Li Qi; Fei Heng; Peter B Gilbert
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2020-05-22       Impact factor: 1.864

9.  Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.

Authors:  Lawrence Corey; Peter B Gilbert; Michal Juraska; David C Montefiori; Lynn Morris; Shelly T Karuna; Srilatha Edupuganti; Nyaradzo M Mgodi; Allan C deCamp; Erika Rudnicki; Yunda Huang; Pedro Gonzales; Robinson Cabello; Catherine Orrell; Javier R Lama; Fatima Laher; Erica M Lazarus; Jorge Sanchez; Ian Frank; Juan Hinojosa; Magdalena E Sobieszczyk; Kyle E Marshall; Pamela G Mukwekwerere; Joseph Makhema; Lindsey R Baden; James I Mullins; Carolyn Williamson; John Hural; M Juliana McElrath; Carter Bentley; Simbarashe Takuva; Margarita M Gomez Lorenzo; David N Burns; Nicole Espy; April K Randhawa; Nidhi Kochar; Estelle Piwowar-Manning; Deborah J Donnell; Nirupama Sista; Philip Andrew; James G Kublin; Glenda Gray; Julie E Ledgerwood; John R Mascola; Myron S Cohen
Journal:  N Engl J Med       Date:  2021-03-18       Impact factor: 176.079

10.  Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

Authors:  Allan C deCamp; Morgane Rolland; Paul T Edlefsen; Eric Sanders-Buell; Breana Hall; Craig A Magaret; Andrew J Fiore-Gartland; Michal Juraska; Lindsay N Carpp; Shelly T Karuna; Meera Bose; Steven LePore; Shana Miller; Annemarie O'Sullivan; Kultida Poltavee; Hongjun Bai; Kalpana Dommaraju; Hong Zhao; Kim Wong; Lennie Chen; Hasan Ahmed; Derrick Goodman; Matthew Z Tay; Raphael Gottardo; Richard A Koup; Robert Bailer; John R Mascola; Barney S Graham; Mario Roederer; Robert J O'Connell; Nelson L Michael; Merlin L Robb; Elizabeth Adams; Patricia D'Souza; James Kublin; Lawrence Corey; Daniel E Geraghty; Nicole Frahm; Georgia D Tomaras; M Juliana McElrath; Lisa Frenkel; Sheila Styrchak; Sodsai Tovanabutra; Magdalena E Sobieszczyk; Scott M Hammer; Jerome H Kim; James I Mullins; Peter B Gilbert
Journal:  PLoS One       Date:  2017-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.